

Plasma Cell Neoplasms


Multiple Myeloma and Related Disorders

A group of diseases that involve malignant proliferation of Ig-secreting cells of B-cell lineage that are usually associated with paraproteinemia or paraproteinuria.

- ❖ Plasma Cell Dyscrasia
 - MGUS
 - Plasmacytoma
- ❖ Multiple myeloma
 - Smoldering
 - POEMS
- ❖ Waldenstrom's Macroglobulinemia
- ❖ Amyloidosis

**Stage B
of cell maturation**

**Corresponding
Malignancy**



The Continuum of Plasma Cell Disorders




Normal

MGUS

Indolent
Myeloma

Multiple
Myeloma



The hallmark of plasma cell disorders is the presence of a **paraprotein in the serum and/or urine.**

Paraproteinemias

❖ Normal immunoglobulin pattern

- Polyclonal reflects progeny of different plasma cells


❖ Paraproteinemia

- Monoclonal immunoglobulin band in sera reflects synthesis from single plasma cell clone


SPEP

Polyclonal
Gammopathy


Monoclonal
Gammopathy



Serum Protein Electrophoresis




Immunofixation



← Normal

Abnormal



Etiology

- ❖ Etiology is not known.
- ❖ Risk factors: Race, sex.
- ❖ Increased risk with ionizing radiation and exposure to pesticides like Dioxin.
- ❖ Recently viruses like HHV-8 and SV-40, have been linked to myeloma development.

Pathogenesis


- ❖ Bone marrow microenvironment very important for proliferation and chemotherapy resistance.
- ❖ BM stromal cells produce IL-6, responsible for pathogenesis and progression.
- ❖ IL-6 inhibits apoptosis of plasma cells.
- ❖ IL-6 contributes to bone loss by stimulating osteoclasts and inhibiting bone formation.
- ❖ Interaction with extracellular matrix proteins protect cells from chemo and radiation.

MM: Clinical Features

- ❖ Disease of the elderly (7th decade)
- ❖ Bone pain
 - most commonly vertebra and long bones
 - Vertebral column – 66%
 - Ribs – 44%
 - Skull – 41%
 - Lytic lesions – 1 to 4 cm in diameter
 - fractures


Multiple Myeloma

Typical “Punched Out” Lesions







Compression Fx T4







Abnormal marrow signal secondary to Multiple Myeloma





Multiple Myeloma



Morphology








Mott cell

Dutcher body



Clinical Course

- ❖ Infiltration of organs esp bones
 - Hypercalcemia
 - Anemia
- ❖ Excess immunoglobulins
 - hyperviscosity
- ❖ Suppression of normal humoral immunity
 - Recurrent infections

❖ Renal Damage

- Bence Jones Proteinuria – tubular toxicity (cast nephropathy)
- Amyloidosis
- Hypercalcemia
- Infections

Diagnostic Criteria

- ❖ M component (any quantity)
- ❖ Bone marrow plasmacytosis (any %)
- ❖ Myeloma related organ or tissue impairment [ROTI]
 - C – hypercalcemia
 - R – renal failure
 - A – anemia
 - B – bone lesions

M component

- ❖ IgG – 55%
- ❖ IgA – 25%
- ❖ Hyperviscosity syndromes

Myeloma Diagnostic Work-Up

- ❖ SPEP and UPEP (24 collection) with immunofixation
 - 3% nonsecretory: check serum free light chains
- ❖ Skeletal survey
- ❖ Quantitative serum immunoglobulins (IgA, IgG, IgM)
- ❖ Bone Marrow Aspirate and Biopsy
- ❖ *Other tests (calcium, creatinine, beta-2 microglobulin, CRP, albumin, plasma cell labeling index, etc, etc) are only for staging/prognosis*

Prognosis

❖ Poor

❖ Survival – 6 to 12 months if untreated

❖ Bad Prognosis

- Hemoglobin <8.5
- Calcium >12
- >3 lytic bone lesions
- High M-protein
 - IgG >7 g/dL
 - IgA >5 g/dL
 - Bence Jones >12 g/24h

Solitary Plasmacytoma

- ❖ 3 to 5 % of plasma cell neoplasms present as solitary lesion of bone or soft tissue
- ❖ Osseous – same sites as myeloma
- ❖ Extra osseous – lung, oro/nasopharynx, nasal sinuses
- ❖ Progression to myeloma common in solitary osseous.

Osteosclerotic Myeloma (POEMS)

- ❖ Polyneuropathy
 - Sensorimotor peripheral neuropathy in 75%
- ❖ Organomegaly
 - Lymphadenopathy, hepatomegaly, splenomegaly
- ❖ Endocrinopathy
 - Adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic
- ❖ M-Protein
- ❖ Skin changes
 - Hyperpigmentation, hypertrichosis, plethora, hemangiomata, white nails

Osteosclerotic Myeloma



MGUS

- ❖ Dysproteinemia without associated disease
- ❖ Most common cause of monoclonal gammopathy.
- ❖ 1% progress to myeloma every year
- ❖ M protein < 3g/dL
- ❖ No BJP

Smoldering Myeloma

- ❖ Serum M-protein >3 g/dL
- ❖ Marrow plasma cells >10%
- ❖ No lytic bone lesions, unexplained anemia, hypercalcemia, or renal insufficiency
- ❖ Evolve to overt multiple myeloma
 - 3.3% per year
 - Greatest for IgA

Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)

- ❖ Malignant proliferation of plasmacytoid lymphocytes secreting IgM M-protein
- ❖ Organomegaly/Peripheral neuropathies
- ❖ Cryoglobulinemia
 - Type I: Raynaud's phenomenon, cold urticaria, etc.
 - Type II: Purpura, arthralgias, renal failure, mononeuritis
- ❖ IgM tissue infiltration/AL amyloidosis
- ❖ Coagulation abnormalities

Hyperviscosity

- ❖ Usually IgM >5 g/dL, viscosity >4.0
- ❖ Eyes
 - “Sausage link” conjunctival and retinal veins
 - Retinal hemorrhages, Papilledema
- ❖ CNS
 - Ataxia, nystagmus, vertigo, confusion, altered consciousness
- ❖ Increased intravascular volume
 - Dilutional anemia
 - Risk congestive heart failure with transfusion
- ❖ Therapy: plasmapheresis/chemotherapy



Thank You